Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


GSK research facility produces ‘vision of pharmacy’s future’

GSK wants to help to 'future proof' community pharmacies

GlaxoSmithKline (GSK) is preparing to unveil its vision of a “pharmacy of the future”, the manufacturer has announced.

GSK has used research conducted at its Shopper Science Lab (pictured), which it opened in Brentford in 2013, to identify the changing needs of customers, help pharmacists “future-proof” their businesses and improve the health of patients, it said.

GSK’s vision of the future will involve improving shoppers’ experience by enhancing pharmacists’ capabilities through “accessible, patient-centric training programmes” and tailoring products and services, it promised.

Andy Gill, pharmacy sales director at GSK, said the strategy is an extension of the work many pharmacies are already doing, and GSK is “pleased to be bringing this exciting new vision to the fore”.

For more information, contact your local GSK sales representative

Do you think this research will provide practical help for your pharmacy?


Stamford, Lincolnshire
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts